Ramucirumab

02/01/2018 - "The REGARD trial demonstrated that ramucirumab monotherapy improved both overall survival (OS) and progression-free survival (PFS) compared with best supportive care plus placebo as second-line treatment for patients with advanced gastric cancer. "
04/20/2021 - "Ramucirumab (RAM) has been proven effective against unresectable or recurrent gastric cancer. "
12/01/2020 - "Recently, ramucirumab monotherapy is administered for advanced HCC patients and expect to be effective in AFP producing gastric cancer. "
01/01/2018 - "Ramucirumab has recently proved to be effective for advanced or recurrent gastric cancer (AGC). "
10/01/2016 - "Phase III trials in advanced gastric cancer have demonstrated improved outcome with ramucirumab as second-line treatment. "

01/01/2022 - "Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials."
08/01/2020 - "In this meta-analysis of RCTs, use of ramucirumab in patients with advanced cancer was associated with increased risk of treatment related serious and possibly fatal adverse events but the magnitude of clinical benefit from ramucirumab was mostly negligible with no trial reporting an improvement in QOL. "
01/01/2019 - "Our study suggests that CT value changes of tumors may be a predictor for the efficacy of ramucirumab in aGC."
12/01/2013 - "REGARD was the first phase III study to report on the efficacy of single-agent ramucirumab in patients with advanced cancer. "
01/01/2021 - "The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs."

01/01/2019 - "Clinical utility of ramucirumab in non-small-cell lung cancer."
05/01/2017 - "Ramucirumab in the treatment of non-small cell lung cancer."
01/01/2017 - "Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity."
01/01/2017 - "The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer."
12/01/2016 - "Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer."

05/01/2015 - "Ramucirumab plus FOLFIRI significantly improved overall survival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic colorectal carcinoma. "
01/01/2020 - "Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer."
06/01/2016 - "The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer."
08/01/2022 - "A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer."
09/01/2020 - "Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials."

06/01/2020 - "Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma."
12/01/2020 - "The objective of this study was to investigate the safety, preliminary efficacy, pharmacokinetics, and immunogenicity of ramucirumab plus FOLFOX4 as first-line treatment in patients with advanced hepatocellular carcinoma (HCC). "
12/01/2020 - "Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study."
12/01/2020 - "The combination of ramucirumab (8 mg/kg intravenous, day 1 every 2 weeks) and FOLFOX4 as first-line treatment in patients with advanced hepatocellular carcinoma (HCC) was not sufficiently tolerated. "
01/01/2023 - "The aim of this study was to investigate the factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment. "